MA med tech outfits still wary of the device tax

The Affordable Care Act's 2.3% tax on medical device revenue is meant to pay for itself through a long-term boost in insured patients, but execs in the med tech hotbed of Massachusetts remain unconvinced. According to a Massachusetts Medical Device Industry Council survey, only 8% of respondents believe the growing ranks of insured Americans will offset the charge, with some echoing the argument that newly enrolled patients tend to be young and thus not in need of the orthopedic and cardiac devices that line the industry's pockets. Article

Suggested Articles

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.

Akoya Biosciences raised $50 million to help boost its commercialization in research, drug development and clinical testing markets.